Novel Diagnostic Test for Tuberculosis

Chemogen's proprietary and patented technology for the diagnosis of tuberculosis (TB) in immunocompromised people marks a new chapter in the fight against Tuberculosis. More than 2 billion people, or a third of the population worldwide, are infected with Mycobacterium tuberculosis, the bacteria that causes TB. About 9 million people develop active TB each year and close to 2 million will die.
As the leading killer of HIV-infected people, diagnosis of TB in such people remains a challenge. Today's most commonly used TB diagnostic, sputum microscopy, is more than 100 years old. It detects only half of the cases of TB cases in patients tested, and far fewer in people with HIV/AIDS. As a consequence, many co-infected patients die without ever receiving a diagnosis. Without proper treatment, approximately 90% of HIV-positive patients die of TB within months of infection.